A Study of Zanubrutinib Versus Lenalidomide in Participants With Relapsed/Refractory Marginal Zone Lymphoma

A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma

Beigene Study ID

BGB-3111-308

ClinicalTrials.gov ID

NCT05100862

EudraCT Number

2022-502548-12-00

China Drug Trials ID

CTR20232545

Study Overview

Sex: All

Age: 18 Years / N/A

No Study Documents

Locations

Study Overview

Sex: All

Age: 18 Years / N/A

No Study Documents